Abstract: A therapeutics delivery system, and methods of making and using same, are disclosed for environments that rapidly clear any injected therapeutics, such as a patient's eye. The therapeutics delivery system releases the drug in a therapeutically effective concentration for a desired duration of time with a predefined drug kinetics. In one embodiment, the embodiments of the present disclosure release a therapeutically effective concentration for a longer time period than other delivery systems, for instance from a day to a week. Certain embodiments comprise a therapeutics dispensing device comprising a biodissolvable hydrogel matrix for long term drug release that allows the device to be placed directly at the injured site, e.g., onto the surface at or near the injury, and retained there rather than through injection, whether locally or systematically.
Type:
Application
Filed:
August 6, 2013
Publication date:
July 9, 2015
Applicant:
Baylor College of Medicine
Inventors:
Ghanashyam Acharya, Stephen C. Pflugfelder, Cintia S. De Paiva, Jennifer L. Simpson
Abstract: Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for inducing expression of paternal UBE3A in cells and animals.
Type:
Application
Filed:
June 25, 2013
Publication date:
July 9, 2015
Applicants:
Baylor College of Medicine, Isis Pharmaceuticals, Inc.
Inventors:
Frank Rigo, Amanda Ward, Linyan Meng, Arthur L. Beaudet
Abstract: The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.
Type:
Grant
Filed:
November 17, 2010
Date of Patent:
June 30, 2015
Assignee:
Baylor Research Institute
Inventors:
Raphael Schiffmann, Fanny Mochel, Lawrence Sweetman, Sabrina Forni
Abstract: The disclosure provides an electromagnetic (EM) sensor system and method that permits rapid and non-invasive measurement of material properties using measurements of the dispersion of EM energy signals over a wide band of frequencies, including second and higher order moments. The EM energy can be a pulse signal, including an ultra-wide band (“UWB”) pulse signal. A plurality of signals can be incrementally projected through the material in a grid. The grid can generally include a series of projections through the material of an object at different angles. The further analysis of the dispersion characteristics of the EM energy signal provides a measure of added features that assist in improved characterization of the material properties. In at least one embodiment, the results of processed pulses through the object can be used to form a two-dimensional or three-dimensional image of the material for the particular property being measured.
Abstract: The present invention concerns methods and compositions regarding one or more microRNAs or variants thereof that are provided to an individual for a variety of medical treatments, including sensitization to cancer therapy or prevention of a cancer to become sensitized to a cancer therapy. In specific embodiments, the microRNAs include miR-520a (including at least miR-520a-3p and miR-520-5p), miR-520g, miR-520h, and functional variants thereof. In some embodiments, the cancer is ovarian cancer, and in particular embodiments, the cancer therapy is platinum-based chemotherapy.
Type:
Application
Filed:
July 12, 2013
Publication date:
June 11, 2015
Applicants:
University of Houston, Baylor College of Medicine
Inventors:
Matthew L. Anderson, Claire Mach, Preethi Gunaratne
Abstract: The present invention includes compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of allergy, and asthma.
Type:
Grant
Filed:
August 28, 2012
Date of Patent:
June 2, 2015
Assignee:
Baylor Research Institute
Inventors:
SangKon Oh, Jacques F. Banchereau, Gerard Zurawski, Hideki Ueno, Ling Ni
Abstract: The invention relates to bone compression devices and bone compression systems, and in particular, to bone compression devices and systems for use in connection with vertebrae. The bone compression devices and bone compression systems are disposed, or installed, along at least one bone to maintain the at least one bone in a desired spatial relationship. Broadly, the invention is directed to a bone compression device for placing in communication with at least one bone having a bone radius of curvature, the bone compression device comprising a plate having a pre-formed shape, a deformed shape, and at least one elastic shape therebetween, the pre-formed shape having a pre-formed radius of curvature less than the bone radius of curvature, the deformed shape having a deformed radius of curvature greater than the bone radius of curvature, and at least one of the at least one elastic shapes having an elastic radius of curvature that substantially corresponds to the bone radius of curvature.
Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
Type:
Grant
Filed:
March 5, 2013
Date of Patent:
April 7, 2015
Assignee:
Baylor College of Medicine
Inventors:
David Spencer, Brent Hanks, Kevin Slawin
Abstract: A method for adaptively determining a model of visual performance of a test subject comprising the step of exposing a test subject to a plurality of trials. Each trial comprises the steps of identifying the stimulus pattern to test, generating a stimulus pattern on a display, determining whether the stimulus pattern generated an OKR, updating the model to incorporate the OKR results, and determining whether the updated model is acceptable. The trials can be iteratively repeated until the model for visual performance is acceptable.
Type:
Grant
Filed:
January 2, 2013
Date of Patent:
March 31, 2015
Assignee:
Baylor College of Medicine
Inventors:
Benjamin J. Frankfort, Cameron S. Cowan, Samuel Miao-sin Wu
Abstract: A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, MiR-198 replacement reverses tumorigenicity in vitro and in vivo. embodiment of the disclosure is a method of treating cancer in an individual, comprising the step of increasing the level of active microRNA-198 molecules in the pancreatic cancer tumor cells of the individual by an amount sufficient to cause an improvement in the pancreatic cancer in the individual.
Type:
Grant
Filed:
August 6, 2012
Date of Patent:
March 24, 2015
Assignee:
Baylor College of Medicine
Inventors:
Qizhi Yao, Christian Marin-Muller, Changyi Chen
Abstract: A method and system to induce bone growth by locally delivering bone morphogenetic proteins (BMPs) to the target location for a prolonged period without invasive procedures are disclosed. The new bone growth is induced by delivering cells producing BMPs from transduced viral vectors to the target cite. In various embodiments, the cells are encapsulated in hydrogel microspheres that are non-degradable or degradable by enzymes produced during the bone formation process. Various embodiments may be used to induce spinal fusion or repair critical bone defects.
Type:
Grant
Filed:
December 1, 2010
Date of Patent:
February 24, 2015
Assignees:
Baylor College of Medicine, William Marsh Rice University
Inventors:
Alan R. Davis, Elizabeth A. Davis, Kevin Moran, Ronke Olabisi, Jennifer L. West, Christy Franco
Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
Type:
Grant
Filed:
March 4, 2010
Date of Patent:
February 24, 2015
Assignee:
Baylor Research Institute
Inventors:
Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
Abstract: A simple, rapid, inexpensive, and promising commercial biomarker assay method for multiple diseases is described herein. The present invention detects miRNA-based biomarkers in human stool specimens. The method of the present invention amplifies miRNA directly from stool specimens without any prior miRNA extraction. Differential expression of specific microRNAs in stool of colorectal cancer CRC and adenoma patients suggest fecal microRNAs as a novel potential biomarker for colorectal neoplasia detection. The method of the present invention has diagnostic, prognostic, and therapeutic relevance for gastroenterological cancers/colorectal cancer and as well as further acquired or hereditary GI diseases.
Type:
Grant
Filed:
October 8, 2010
Date of Patent:
February 17, 2015
Assignee:
Baylor Research Institute
Inventors:
Ajay Goel, C. Richard Boland, Alexander Link, Francesc Balaguer
Abstract: Method and system are disclosed for characterizing and quantifying composite laminate structures. The method and system take a composite laminate of unknown ply stack composition and sequence and determine various information about the individual plies, such as ply stack, orientation, microstructure, and type. The method and system can distinguish between weave types that may exhibit similar planar stiffness behaviors, but would produce different failure mechanisms. Individual ply information may then be used to derive the laminate bulk properties from externally provided constitutive properties of the fiber and matrix, including extensional stiffness, bending-extension coupling stiffness, bending stiffness, and the like. The laminate bulk properties may then be used to generate a probabilistic failure envelope for the composite laminate.
Type:
Application
Filed:
March 20, 2013
Publication date:
February 12, 2015
Applicant:
BAYLOR UNIVERSITY
Inventors:
David A. Jack, John E. Fitch, Theresa Vo
Abstract: The present disclosure describes genetically-modified plants having enhanced tolerance to multiple abiotic stressors, such as extreme temperatures (heat or cold) and/or drought. Abiotic stress tolerance is enhanced by ectopic expression of a heterologous glutaredoxin. Abiotic stress tolerance (particularly drought) is also enhanced by inhibited function, activity, or expression of an endogenous glutaredoxin. Methods of producing such genetically-modified plants are also disclosed.
Type:
Application
Filed:
August 31, 2012
Publication date:
February 5, 2015
Applicants:
BAYLOR COLLEGE OF MEDICINE, KANSAS STATE UNIVERSITY RESEARCH FOUNDATION
Inventors:
Sunghun Park, Frank White, Jungeun Park, Kendal Hirschi, Ning-Hui Cheng
Abstract: The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.
Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
Type:
Application
Filed:
February 7, 2014
Publication date:
December 11, 2014
Applicant:
BAYLOR RESEARCH INSTITUTE
Inventors:
Jacques F. Banchereau, Maria Virginia Pascual
Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.
Type:
Grant
Filed:
February 7, 2014
Date of Patent:
December 9, 2014
Assignee:
Baylor College of Medicine
Inventors:
Lawrence Chan, Hideto Kojima, Tomoya Terashima